Navigation Links
Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
Date:1/24/2008

RESEARCH TRIANGLE PARK, N.C., Jan. 24 /PRNewswire/ -- Quintiles Transnational Corp. today announced the completion of its previously announced new investor partnership to support the company's continued growth under the leadership of founder and current Chairman and CEO Dennis Gillings, CBE, and the management team. Gillings and global private investment firms Bain Capital and TPG Capital have become the lead investors in Quintiles, with 3i also becoming a significant investor. Temasek Holdings remains an investor in Quintiles. As part of the transaction, One Equity Partners, the private equity arm of JPMorgan Chase (NYSE: JPM), has sold its stake in the company to the new investor partnership. Terms of the transaction were not disclosed. The company incurred no new debt as a result of the deal.

About Quintiles Transnational

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With about 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's web site at http://www.qtrn.com.

About Bain Capital

Bain Capital (http://www.baincapital.com) is a global private investment firm that manages several pools of capital including private equity, venture capital, public equity and leveraged debt assets with more than $65 billion in assets under management. Since its inception in 1984, Bain Capital has made private equity investments and add-on acquisitions in over 250 companies around the world, and has a team of almost 300 professionals dedicated to investing in and supporting its portfolio companies. Bain Capital has a long history of investing in healthcare, with investments in more than 50 companies including HCA, Warner Chilcott, CRC Health Group, Stericycle, M|C Communications, Wesley Jessen, and Physio Control. Headquartered in Boston, Bain Capital has offices in New York, London, Hong Kong, Shanghai, Tokyo and Munich.

About TPG Capital

TPG Capital is the global buyout group of TPG, a leading private investment firm founded in 1992, with more than $35 billion of assets under management and offices in San Francisco, London, Hong Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park, Moscow, Mumbai, Beijing, Shanghai, Singapore and Tokyo. TPG Capital has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, joint ventures and restructurings. Please visit http://www.tpg.com.

About 3i

Established in 1945, 3i is an international leader in private equity and venture capital with assets of $16 billion. 3i invests across Europe, North America and Asia. Our competitive advantage comes from our international network with more than 250 investment professionals in 14 countries, unrivaled sector depth and an extensive portfolio of approximately 750 companies. These underpin the value that we deliver to our portfolio and to our shareholders. Please visit http://www.3i.com.

About Temasek Holdings

Incorporated in 1974, Temasek Holdings is an Asia investment firm headquartered in Singapore. Temasek has a multinational staff of 300 people. Supported by affiliates and offices around Asia, it manages a diversified S$164 billion (US$108 billion) portfolio, focused primarily in Asia. Temasek is a shareholder and investor in diverse sectors such as banking & financial services, real estate, transportation & logistics, infrastructure, telecommunications & media, bioscience & healthcare, education, consumer & lifestyle, engineering & technology, as well as energy & resources.


'/>"/>
SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quintiles to Open Clinical Research Office in Wilmington, NC
2. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
3. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
4. Expert Cardiologist Joins Quintiles Medical Group
5. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
6. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
7. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. China Medical Technologies Completes Acquisition of BBE
9. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
10. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
11. Pharmos Corporation Completes Initial Closing of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... für Molekulargenetik, erweitert seine Palette an anpassbaren SureSeq™ ... Custom FH Panels, das ein schnelles und kostengünstiges ... Das Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single ... mit einem einzigen kleinen Panel und ermöglicht eine ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... announces the commercial launch of flexible packaging for their exceptionally efficient human ... bag system extends RoosterBio’s portfolio of bioprocess media products engineered to radically ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:11/14/2016)... Fla., Nov. 14, 2016  xG Technology, Inc. ("xG" ... providing critical wireless communications for use in challenging operating ... September 30, 2016. Management will hold a conference call ... 5:00 p.m. Eastern Time (details below). Key ... a $16 million binding agreement to acquire Vislink Communication ...
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
Breaking Biology News(10 mins):